The prognostıc markers, current treatment strategıes and the long term prognosıs for prolıferatıve forms of lupus nephrıtıs by Tuğlular, Serhan & Yavuz, Şule
Review
T H E  P R O G N O S T I C  M A R K E R S ,  C U R R E N T  T R E A T M E N T  
S T R A T E G I E S  A N D  T H E  L O N G  T E R M  P R O G N O S I S  F O R  
P R O L I F E R A T I V E  F O R M S  O F  L U P U S  N E P H R I T I S
Serhan Tuğlular, M .D .* /  Şule Yavuz, M .D .**
'  S u b -d e p a rtm e n t o f  n e p h ro lo g y , D e p a rtm e n t o f  In te rn a l M ed ic in e , S cho o l o f  M ed ic ine , 
M a rm a ra  U nivers ity , Is tan b u l, Turkey.
* ’ S u b -d e p a rtm e n t o f  R heu m ato log y , D e p a rtm e n t o f  In te rn a l M ed ic in e , S ch o o l o f  M ed ic ine, 
M a rm a ra  U nivers ity , Is ta n b u l, Turkey.
ABSTRACT
Renal manifestations of systemic lupus 
erytematosus (SLE) are highly variable in clinical 
presentation, ranging from mild asymptomatic 
proteinuria to rapidly progressive 
glomerulonephritis leading to end stage renal 
disease.
Renal biopsy evaluated by light microscopy, 
immunofluorescence and electron microscopy 
where possible, provides invaluable information 
for the proper histopathological classification and 
for assessing the disease activity and chronicity. 
The World Health Organization (WHO) 
classification of lupus nephritis is a practical and 
widely accepted system for categorizing the main 
renal lesions observed on biopsies of patients 
with lupus nephritis(Table I) (1). The focal and 
diffuse proliferative forms of lupus nephritis 
corresponding to WHO class III and IV have the 
worst prognosis, leading to ESRD in 20-30% of 
the cases (2). A substantial proportion of patients 
with class III nephritis progress to class IV 
disease and it has been suggested that these two 
classes are qualitatively similar and simply reflect 
milder or more severe stages respectively (3).
The aim of this article is to overview the 
prognostic markers, the current treatment 
strategies and the long term prognosis for the 
latter forms of lupus nephritis.
PROGNOSTIC MARKERS
The proliferative forms of lupus nephritis are 
characterized with endocapillary proliferation, 
capillary loop necrosis and wire loop formation on 
light microscopy and abundant deposits of all 
classes of immunoglobulins along the capillary 
walls on immunoflourescent microscopy. These 
features are considered potentially active but 
reversible (3).
Clinical studies have demonstrated the utility of 
the WHO classification in stratifying patients 
according to risk of renal disease progression. 
However, in addition to this classification, further 
emphasis on the potential roles of the diverse 
glomerular, tubular, interstitial and vascular 
lesions have demonstrated that better prediction 
for renal survival can be made with 
subclassification of the WHO system aiming to 
include the extent of the injury to the various
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components of the kidney listed above. These 
subclassifications provide a semiquantitative 
analysis of acute and chronic renal injury. 
Markers of acute injury (activity index (Al)) 
include intracapillary proliferation, epithelial 
crescents, glomerular polymorphonuclear 
infiltration, wire loop lesions, intracapillary 
thrombi, fibrinoid necrosis and/or karyorrhexis, 
hematoxylen bodies, vasculitis and diffuse 
interstitial inflammation. Activity index ranges 
from 0-24 depending on the presence and extent 
of the above stated lesion. Chronic changes 
(chronicity Index (Cl)) include glomerular 
obsoloscence, segmental glomerular hyalinosis, 
interstitial fibrosis, tubular atrophy and arteriolar 
hyalinosis. Cl reflects the features of chronic 
Irreversible damage and the score ranges from 0- 
12. It should, nevertheless, be emphasized that 
the biopsy provides information regarding acute 
and chronic renal injury at a single time point. 
Transformation of renal lesions for better or 
worse can occur both spontaneously or as a 
result of treatment. Reproducibility of the activity 
and chronicity indices in experienced hands has 
been considered excellent (3). Aggressive 
therapy may alter the prognostic significance of a 
high activity index (4). However, patients with a 
high chronicity index, are at risk for developing 
progressive renal disease, despite aggressive 
immunosuppressive treatment (5,6). On the 
other hand, the extent of chronic irreversible 
renal injury should be considered when weighing 
the costs and benefits of aggressive 
immunosuppression.
NIH studies have revealed that an elevated Al 
(>12/24) and Cl (>2/12) is associated with a poor 
renal prognosis: Long term renal survival with
Cl<2/12 corresponding to a 10yr survival of 
100%, while Cl from 2-4/12 had a 10yr survival of 
70% and a Cl>4/12 had a 10 yr survival of only 
35%. In other studies, including the recent article 
by llei et al. addressing a large population of 
patients with severe diffuse proliferative disease, 
neither Al nor Cl predicted renal outcome.
Studies investigating the prognostic role of renal 
flares in patients with lupus nephritis are limited. 
Moroni et al (7) have evaluated the prognostic 
role of the renal flares in 70 patients with lupus 
nephritis followed for 5-30 years. The end-point of 
the study was the persistent doubling of plasma 
creatinine. Patients who developed renal flares
had significantly more probability of reaching the 
end point than patients who had never had flares 
(P=0.03; RR:6.8). Among the patients with 
proteinuric flares, none eventually doubled his or 
her plasma creatinine after a median follow-up of 
10 years. In contrast, the probability of reaching 
the end-point was significantly higher in patients 
who had nephritic flares (P<0.00001: RR:27). 
The hazard of irreversible renal function 
deterioration was higher when plasma creatinine 
did not return to the basal levels within 2 months 
after treatment (p< 0.0001 )
Other clinical and pathological correlates with 
renal flares have been reported as high Al at 
initial biopsy(>9) (8), age under 29yrs at onset of 
renal disease, treatment with corticosteroids 
alone (9), a delay of more than 5 months from the 
onset of nephritis to initiation of cytotoxic therapy
(10) and a short duration of high-dose IV 
cyclophosphamide (11), male sex, presence of 
arterial hypertension at presentation (7), and 
duration of the disease (12). There was a 
significant reduction of renal flares after the 10th 
year from the clinical onset of lupus nephritis 
when compared to the first 10 years.
Since renal flares seem to be strongly correlated 
with long-term renal prognosis, close 
monitorization of these patients for early 
detection and treatment of any exacerbation of 
lupus activity is essential. Serum complement 
levels, inreased levels of C1q antibodies (13), 
increased anti-DNA antibodies (14) have been 
suggested to predict the onset of renal flares. 
However, these immunological markers may also 
have fluctuations without heralding the 
exacerbation of disease activity. Increasing the 
corticosteroid and/or immunosuppressive 
treatment based only on these markers may 
expose the patients to overtreatment, which will 
in turn be associated with increased iatrogenic 
toxicity. Therefore Ponticelli et al have suggested 
the intensification of therapy on the basis of 
double-checked consistent increase in serum 
creatinine and/or daily proteinuria (12).
TREATMENT STRATEGIES
Data provided by several studies, especially 
NIH, have made prednisone in combination with 
cytotoxic immuno-suppressives, either
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cyclophosphamide or azathioprine, the main stay 
of the current treatment for LN WHO Classes III 
and IV (11,15).
The results of several studies proved prednisone 
monotherapy to be insufficient for the 
proliferative forms of LN. Bansal and Beto (16) 
reported a 29% higher chance of developing 
ESRD If treated with prednisone alone. Data 
from the NIH study have demonstrated that 
prednisone was not able to prevent the 
development of chronic lesions(17) while in 
patients treated with cyclophosphamide or 
azathioprine there was no progression of 
chronicity over time (18). The chronicity Index 
has proved itself to be one of the strongest 
indicators of a poor outcome.
On the other hand, the difference in renal survival 
between cyclophosphamide and azathioprin 
treated groups failed to reach statistical 
significance In the well-known study of Steinberg 
et al (19). In fact a direct prospective randomized 
comparison between azathioprin and 
cyclophosphamide is unfortunately lacking. 
Cameron gathered data from the literature in 
1993, comparing the renal survival in patients 
treated with cyclophosphamide with data 
obtained retrospectively in patients treated with 
azathioprine (20). There were no differences 
between the two drugs. However, the fact that 
this was not a prospective analysis and since 
patients with a less severe disease may have 
been treated with azathioprine while 
cyclophosphamide may have been reserved for 
more severe cases, these results cannot be 
considered conclusive.
The Dutch working party on SLE started a 
randomised controlled trial in 1995 to compare 
the NIH cyclophosphamide regimen with a 
regimen containing azathioprine (2 milligrams 
per kilogram) together with méthylprednisolone 
pulses on week 0, 2 and 6 together with 
prednisone (20 millligrams/day for 5 months, 
then tapered to 10 milligrams/day) per day. NIH 
cyclophosphamide regimen consisted of initially 
3 méthylprednisolone pulses on days 1-3 and 6 
cyclophosphamide pulses/monthly, and 
thereafter every 3 months together with 1 mg/kg 
of prednisone tapered until 6 months at a dose of 
10 milligrams.
As for the entry characteristics of 87 patients 
treated according to this protocol; they had a 
rather severe form of lupus nephritis as Indicated 
by the serum creatinine, all had low C-3 levels, 
high levels of anti-double stranded DNA 
antibodies, and a significant proteinuria of 4.8 
grams. There were no statistically significant 
differences between the two groups for these 
parameters.
At 6 months, there were no significant differences 
between the number of relapses, failures, renal 
failures, discontinuation of treatment, 
development of end stage renal disease, or 
death. Furthermore, the serum mean creatinine 
came down from 135mmol/L to 97mmol/L in both 
groups; the proteinuria decreased; the systolic 
blood pressure became lower; the SLEDAI score 
as a measure of disease activity also decreased. 
The complement C3 levels normalised and the 
level of anti-DNA antibodies also significantly 
decreased in both groups at 6 months.
Recently, the results of the Euro-Lupus trial have 
been published by Houssiau et al (21). In the 
latter trial, high dose cyclophosphamide was 
compared to low dose cyclophosphamide. The 
high dose group received cyclophosphamide at 
500mg/m2 (max 1500mg) monthly for 6 months 
and tri-monthly twice thereafter. The low-dose 
group also received cyclophosphamide 
intravenously but at a fixed dose of 500 
milligrams fortnightly for 6 months and every 2 
weeks for 3 months thereafter. Both groups 
received 750 mg pulse methylprednlsone on 
three successive days at the start of the trial and 
continued with prednisone 0.5mg/kg tapered 
every two weeks with 2.5 to finally 5-7.5 mg at 
30 months. Both groups were converted to 
prednisone and azathioprine 2mg/day after 
stopping cyclophosphamide pulses. This study 
included 90 patients of which 40 remained on a 
high dose of cyclophosphamide and 38 on a low 
dose. There was no significant difference for 
treatment failure, between the low dose and high 
dose of cyclophosphamide. The incidence of 
renal flares was comparable in both groups,with 
comparable serum creatinine levels and 
proteinuria at 5 years follow up.
According to the currently available data, 
intravenous cyclophosphamide is of proven 
efficacy, but based on the Euro lupus trial, it may
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be true that we do not need high doses for 
induction. The preliminary results of the Dutch 
trial suggets that IV methylprednisolone is 
probably less toxic, and an effective alternative.
Mycophenolate mofetil (MMF) is another 
promising yet unproven alternative. Its efficacy 
has been demonstrated in an animal model of 
lupus nephritis in MRC/lpr mice with reduction in 
proteinuria, decrease in histological severity and 
glomerular immunoglobulin ad C3 deposition
(22). Chan et al have recently reported the 
results of a randomized trial of 42 patients with 
diffuse proliferative glomerulonephritis 
comparing the effect of MMF (1000 mg bid 
decreased to 500mg bid at 6 months) and 
prednisolone with cyclophosphamide (2.5mg/kg 
po daily) and prednisolone followed by 
azathioprine and prednisolone at 6 months (23). 
Limitations of this study were that only 42 
patients were included,most had minor renal 
impairment, the follow-up period was relatively 
short (12 months) and the patients with poorer 
prognostic markers were not included. In fact 
both groups had comparable results for serum 
creatinine, C3 and albumin levels and 
proteinuria. Flowever, the relapse of nephritis 
occurred in 46% of MMF-treated patients 
compared to only 17% of patients treated with 
cyclophosphamide. Further prospective 
randomized long-term studies are needed to 
prove the beneficial effect of MMF in remission 
induction and/or maintenance phase of treatment 
in proliferative lupus nephritis.
Cyclosporine A (CycA), a calcineurin inhibitor, 
inhibiting the production of IL-2, has been 
efficacious in the treatment of several forms of 
glomerulonephritis such as membraneous 
glomerulonephritis and focal segmental 
glomerulosclerosis. Its use in lupus nephritis has, 
however, been limited to small numbers of 
patients unresponsive to standard regimen. In a 
two years trial of CycA, 26 SLE patients 
unresponsive to standard therapy showed 
decreased activity and proteinuria, improved 
renal morphology and a stable creatinine. A 
randomized trial of CycA for membranous LN at 
the NIH is currently underway.
Biological response modifiers (BRM) are another 
group drugs of promising yet unproven efficacy in 
the treatment of proliferative lupus nephritis.
LJP 394 is a small molecule composed of 
polyglycol platform with 4 attached DNA 
polymers. LJP 394 produced decreased anti- 
DNA Ab production in SLE prone mice along with 
improved renal histology and function. This new 
BRM has been used in a recent large, 
multicenter, controlled randomized trial where it 
decreased anti-DNA Ab production but did not 
prevent flares of lupus nephritis.
Anti-C5A, a monoclonal antibody is currently 
being studied in a randomized trial in idiopathic 
membranous nephritis but not yet in proliferative 
lupus nephritis.
Anti-CD40L, a monoclonal antibody blocking 
the communication between B and T cells has 
been potent and successful in improving renal 
histology, decreasing proteinuria and prolonging 
survival in murine models.
Bindarit, an imidazole molecule, blocks the 
production of MCP-1. This agent has been 
successful in animal models and randomized 
controlled trial of Lupus nephritis is currently on 
the way.
Rituximab is a chimeric mouse-human 
monoclonal antibody against the B cell-specific 
antigen CD20, which selectively and profoundly 
depletes B lymphocytes and has been widely 
used to treat B cell lymphomas. Recent open- 
label studies indicate that rituximab is safe and 
may be efficacious in the treatment of recalcitrant 
lupus nephritis, and continued study with 
randomized clinical trials is justified (24).
Apart from the specific immunosuppressive 
therapy directed to the treatment of lupus 
nephritis, an important issue which should not 
be overlooked from the renal and sytemic 
point of view is the general management 
guidelines that apply to all forms of 
glomerulonephritis and chronic renal disease. 
Vigorous treatment of hypertension, and 
hyperlipidemia has proved itself to be very 
important in all forms of glomerulonephritis. 
Use of angiotensin converting enzyme 
inhibitors has become the first choice in 
patients with glomerulonephritis due to their 
additional antiproteinuric effect.
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